Award4

ACTUATE THERAPEUTICS, INC.

Total Value

$1.6M

Filing Date

Oct 30, 2026

1 transactions

Trade Summary

On Oct 28, 2026, BIOS Fund III, LP, Director, 10% Owner, reported $1.6M of ACTUATE THERAPEUTICS, INC. (ACTU) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $0.53. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: BIOS Fund III, LP
Role: Director, 10% Owner
Location: FORT WORTH, TX

Filing Details

Filing Date: Oct 30, 2026
Transaction Date: Oct 30, 2026
Accession Number: 0001791917-26-000006
Form Type: 4

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Oct 28, 2026	ACTU derivative	64,995	$0.53	Grant/Award	$34.6K
Oct 28, 2026	ACTU derivative	87,743	$0.53	Grant/Award	$46.7K
Oct 28, 2026	ACTU derivative	682,885	$0.53	Grant/Award	$363.6K
Oct 28, 2026	ACTU derivative	194,984	$0.53	Grant/Award	$103.8K
Oct 28, 2026	ACTU derivative	368,304	$0.53	Grant/Award	$196.1K
Oct 28, 2026	ACTU derivative	47,972	$0.53	Grant/Award	$25.5K
Oct 28, 2026	ACTU derivative	82,018	$0.53	Grant/Award	$43.7K
Oct 28, 2026	ACTU derivative	36,056	$0.53	Grant/Award	$19.2K
Oct 28, 2026	ACTU derivative	269,342	$0.53	Grant/Award	$143.4K
Oct 28, 2026	ACTU derivative	82,454	$0.53	Grant/Award	$43.9K
Oct 28, 2026	ACTU derivative	133,073	$0.53	Grant/Award	$70.9K
Oct 28, 2026	ACTU derivative	824,012	$0.53	Grant/Award	$438.8K
Oct 28, 2026	ACTU derivative	126,162	$0.53	Grant/Award	$67.2K

Want live alerts when BIOS Fund III, LP trades again?

Download Insider Trades to track ACTU, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.
(F2)A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.
(F3)Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.
(F4)Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
(F5)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIOS Fund III, LP

(Last)

(First)

(Middle)

C/O BIOS EQUITY PARTNERS

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH

76107

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		64,995		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	64,995	$0	64,995	I	Directly held by Bios 2024 Co-Invest, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		87,743		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	87,743	$0	87,743	I	Directly held by Bios Actuate Co-Invest I, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		682,885		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	682,885	$0	682,885	I	Directly held by Bios Actuate Co-Invest II, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		194,984		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	194,984	$0	194,984	I	Directly held by Bios Actuate Co-Invest III, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		368,304		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	368,304	$0	368,304	I	Directly held by Bios Clinical Opportunity Fund, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		47,972		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	47,972	$0	47,972	I	Directly held by Bios Fund I QP, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		82,018		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	82,018	$0	82,018	I	Directly held by Bios Fund I, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		36,056		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	36,056	$0	36,056	I	Directly held by Bios Fund II NT, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		269,342		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	269,342	$0	269,342	I	Directly held by Bios Fund II QP, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		82,454		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	82,454	$0	82,454	I	Directly held by Bios Fund II, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		133,073		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	133,073	$0	133,073	I	Directly held by Bios Fund III NT, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		824,012		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	824,012	$0	824,012	I	Directly held by Bios Fund III QP, LP⁽³⁾⁽⁴⁾⁽⁵⁾
Warrant (Right to Buy)	$0.5325	10/28/2026		A⁽¹⁾		126,162		10/28/2026⁽²⁾	10/28/2031⁽²⁾	Common Stock	126,162	$0	126,162	I	Directly held by Bios Fund III, LP⁽³⁾⁽⁴⁾⁽⁵⁾

1. Name and Address of Reporting Person^*

BIOS Fund III, LP

(Last)

(First)

(Middle)

C/O BIOS EQUITY PARTNERS

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH

76107

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BIOS Fund III QP, LP

(Last)

(First)

(Middle)

C/O BIOS EQUITY PARTNERS

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH

76107

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BIOS Fund III NT, LP

(Last)

(First)

(Middle)

C/O BIOS EQUITY PARTNERS

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH

76107

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.

2. A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.

3. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.

4. Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.

5. The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.

Remarks:

Exhibit 24 - This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. This first Form was filed by Bios Fund III, LP. The second Form 4 was filed by Bios Fund I, LP.

	Bios Fund III, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact	10/30/2026
	Bios Fund III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact	10/30/2026
	Bios Fund III NT, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001791917-26-000006.

ACTUATE THERAPEUTICS, INC.

Trade Summary

Company Information

Insider Information

Filing Details

Derivative Transactions

Want live alerts when BIOS Fund III, LP trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4